Covid-19 Pathology and Treatment


Our achievement is

1. ILC3s with NRP1 produce higher cytokines than ILC3s without NRP1. [67]

2. TGFβ1– NRP1 signaling enhances ILC2 function and type 2 immunity, which identifies NRP1 as a tissue-specific regulator of lung-resident ILC2s and features an NRP1 regulator as a potential therapeutics for pulmonary fibrosis. [75]


꿋꿋하게 주요 국가의 과학자와 전문의들에게 새로운 치료 이론을 제시했었습니다. 한국에서 만든 치료 이론인데 한국에는 제출조차 못하였습니다. 그러나 결국 입증하였고 이제는 코비드-19를 퇴치할 치료법을 제시했습니다.

Pathology and Anticatalysis treatment of exacerbated COVID-19

Viral Respiratory Diseases on Sorok Island during the Pandemic

Benefits of Using Dapsone in Patients Hospitalized with COVID-19

Inflammasome Treatment against Adverse Events of Special Interest

Commentary for the Elderly in the Pandemic Era

Specific Treatment Exists for SARS-CoV-2 ARDS

4,4′-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor

Pathology and Anticatalysis treatment of exasperated COVID-19


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces immune-mediated diseases, which pathophysiology involves the angiotensin-converting enzyme 2 (ACE2) receptor, Toll-like receptor 4 (TLR4) pathway, neuropilin‑1 pathway, inflammasome activation pathway, sterile alpha motif (SAM) and histidine-aspartate domain (HD)-containing protein 1 (SAMHD1) tetramerization pathway, cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway, spike protein/inflammasome-genetic pathway, and immunological memory engram pathway. Therefore, it is necessary to prescribe anticatalytic treatments for type I interferonopathies to alleviate the exacerbated COVID-19 and take the lag time to activate innate or adaptive immune cell reactions.

ClinicalTrials.gov Identifier: NCT04918914

https://clinicaltrials.gov/ct2/show/NCT04918914

The goal of treatment is to reduce the severity of the infectious disease to the level of the flu.

ClinicalTrials.gov Identifier: NCT04935476

https://clinicaltrials.gov/ct2/show/NCT04935476

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (DAP-CORONA)

코비드-19 병리와 치료 이해 ii.pdf